steerBIO GmbH is a boutique management consultancy for the VC, biotech and pharmaceutical industry. We support your complex R&D challenges associated with modern drug development and medical launch by integrating deep knowledge, honest analysis and strategic thinking in a co-creative approach.
Products, services, technology
- Strategic R&D guidance: translational, integrated and access oriented in areas of immunology, ophthalmology and oncology.
- Support with CDPs and TPPs
- DD support focused on integrated R&D strategy across therapeutic areas and treatment modalities
- Interim management
Cooperation possibilities
We are happy to cooperate as functional experts as part of a larger cross-functional team, e.g. as interim management, in-house/out-house hybrid lifecycle teams, or due diligence support.
- http://www.steerbio.com
- +41 79 267 19 27
- Send an email
- Markus John
Some insights
Our company is involved in optimizing drug discovery and drug development to bring more therapies to patients in need.
The past year has been focused to support the launch of a new neuro-immunology company, hopefully it will have a significant patient impact in the future.
With a European focus, in Pharma it is probably Roche and Novartis, in Biotech ArgenX and in VC, Forbion.
He helps to bring medicines to patients and enjoys to be an entrepreneur.
Stakeholders, vs potential collaborators or customers? Stakeholders are probably chamber of commerce, and politicians? Would be nice to discuss whether AHV should invest in Swiss Biotech Ecosystem, just like the Norwegians and British government funds invest in biotech and health ecosystem.